Bayer is suing insurance giant AIG, alleging decades-old insurance policies should have helped cover billions of dollars in legal costs from Roundup and PCB cases now being shouldered by the German ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The timing of Bayer's lawsuit ...

Bayer shares rose as much as 15% on Tuesday after the U.S. solicitor general backed the company’s bid to get the Supreme Court to curtail litigation alleging its Roundup pesticide causes cancer.

Bayer stock jumped on Monday after the German healthcare company said a late-stage stroke drug trial achieved its goals, a development that also helped a rival creating a competing drug. Bayer didn’t ...

Shares in Bayer rose after the company reported positive results from a clinical trial for an experimental stroke-preventing drug which had previously showed to be ineffective in another trial. The ...

The Food and Drug Administration (FDA) on Wednesday granted accelerated approval to Bayer AG‘s (OTC: BAYRY) Hyrnuo (sevabertinib) for adults with a specific type of advanced lung cancer. The approval ...

A Bayer drug designed to target tumors driven by a rare genetic mutation now has accelerated FDA approval, providing another treatment option for certain patients with advanced cases of lung cancer.

Just a few months after Boehringer Ingelheim broke into the oncology space with the first drug that can target a rare tumor type in patients with non-small cell lung cancer (NSCLC), the FDA has given ...

Bayer has built a home for Chinese biopharma companies. Located in Beijing, the Bayer E-Town Open Innovation Center will incubate local biotechs starting with Puhe BioPharma and Youngen Technology.

Bayer AG BAYRY reported third-quarter 2025 core earnings of 17 cents per American Depositary Receipt (ADR), which comfortably beat the Zacks Consensus Estimate of 13 cents per ADR. The company ...

Bayer has cleared out four cancer candidates from its early-stage pipeline, including a STAT3 inhibitor acquired as part of its buyout of Vividion Therapeutics. The Vividion asset in question, called ...

Bayer BAYN1.63%increase; green up pointing triangle reported a net loss for the third quarter due to litigation charges, though adjusted earnings rose, and said it aims to significantly contain risks ...